Extra shots for extra protection? RSV vaccine tested on vulnerable patients
NCT ID NCT07050732
Summary
This study is testing the RSV vaccine Arexvy in people with weakened immune systems, such as organ transplant recipients. Researchers want to see if getting one or two doses provides a better immune response. Participants will receive vaccines over a year and report any side effects to help understand the vaccine's safety and effectiveness in this vulnerable group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.